iRadimed Corporation (NASDAQ:IRMD) Plans Quarterly Dividend of $0.20

Key Points

• iRadimed announced a quarterly dividend of $0.20 (annualized $0.80) with a record date of May 15 and payable May 29, implying a ~0.9% yield and a payout ratio of about 40% — indicating the dividend is covered by current earnings.
• Q1 results beat expectations as the company reported stronger-than-expected EPS and revenue with improved margins and record GAAP EPS, and it issued FY2026 guidance of $2.06–$2.21 EPS while Q2 revenue guidance of $20.0–$21.0M is modestly below consensus, creating near-term execution risk.
• Shares jumped intraday to $87.15 on heavy volume; the company has a market cap of roughly $1.11 billion and a PE near 49.8, and the CEO disclosed a small, pre‑planned Rule 10b5‑1 share sale (generally viewed as neutral).

iRadimed Corporation (NASDAQ:IRMD - Get Free Report) announced a quarterly dividend on Friday, May 1st. Investors of record on Friday, May 15th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, May 29th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th.

iRadimed has a payout ratio of 40.2% indicating that its dividend is sufficiently covered by earnings. Analysts expect iRadimed to earn $2.16 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 37.0%.

iRadimed Price Performance

NASDAQ:IRMD traded up $3.71 during mid-day trading on Friday, reaching $87.15. The stock had a trading volume of 346,336 shares, compared to its average volume of 86,565. iRadimed has a 12 month low of $50.31 and a 12 month high of $107.90. The stock has a market capitalization of $1.11 billion, a PE ratio of 49.80 and a beta of 1.11. The stock has a 50-day simple moving average of $96.69 and a two-hundred day simple moving average of $93.87.

iRadimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.05. iRadimed had a return on equity of 23.83% and a net margin of 26.82%.The firm had revenue of $22.69 million during the quarter, compared to analysts' expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities analysts expect that iRadimed will post 1.94 EPS for the current year.

iRadimed News Roundup

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Q1 earnings and revenue beat consensus: iRadimed reported non‑GAAP EPS of $0.49 (GAAP $0.45) and revenue of ~$22.0M, both above expectations, with year‑over‑year EPS and revenue growth — a primary driver of the intraday rally. iRadimed (IRMD) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Record GAAP and improved margins: management highlighted record GAAP diluted EPS and improved net margin/ROE metrics, signaling operating leverage and pricing/volume strength. IRADIMED Reports First Quarter 2026 Financial Results
• Positive Sentiment: Dividend increase maintained: the company announced a regular quarterly cash dividend of $0.20 (up from $0.17), which supports income-oriented investors and signals confidence in cash flow. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Full‑year guidance reaffirmed and nudged slightly above consensus: FY2026 EPS guidance was set to $2.06–$2.21 (consensus ~2.05), and revenue guidance roughly $91–96M (consensus ~$92.4M) — supportive but not a major beat. IRADIMED Reports First Quarter 2026 Financial Results
• Neutral Sentiment: CEO insider sale disclosed: CEO Roger Susi sold 3,750 shares under a pre‑arranged Rule 10b5‑1 plan — a small, orderly sale that management says was planned, so likely neutral for most investors. Insider Selling: iRadimed CEO Sells Shares
• Negative Sentiment: Q2 revenue and mid‑point EPS guidance slightly cautious vs. street: Q2 revenue guidance of $20.0–$21.0M is modestly below consensus (~$21.1M) and Q2 EPS guidance (0.44–0.48) straddles the street estimate — this introduces short‑term execution risk that could temper gains. IRADIMED Reports First Quarter 2026 Financial Results

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.